“ophthotech” Archives

in
Entry Author Date Location
As AMD Race Tightens, Regeneron’s Second Eye Drug Combo Falls Short 11/27/17 New York
Gemini Reels In $42M to Target Root Causes of Age-Related Blindness 10/17/17 Boston
Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More 08/18/17 National
Ophthotech’s Final Try at Combo Eye Drug Comes up Short 08/14/17 New York
Bio Roundup: Travel Ban, Pharma in DC, Biogen Splits, PCSK9 Wins 02/03/17 National
After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies 12/16/16 New York
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More 12/16/16 National
Ophthotech Eye Drug Fails Badly in Pivotal Test, Shares Crumble 12/12/16 New York
Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More 11/04/16 National
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
Ocular Therapeutix Inks Licensing Deal With Regeneron For Wet AMD 10/13/16 Boston
East Coast Biotech Roundup: Pfizergan, Zafgen, Codiak, Boston Pharma 11/23/15 Boston
Aveo, Still Breathing, Cuts New Deal With Novartis 08/17/15 Boston
Former Roche, Alexion Execs Head to Ophthotech 07/21/15 New York
Good Times Roll on for Biotech VCs As Clarus Bags New $500M Fund 06/09/15 Boston
East Coast Biotech Roundup: Regeneron, Sage, Tara, Alnylam, & More 11/14/14 Boston
East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More 09/15/14 Boston
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More 05/27/14 Boston
Ophthotech, Novartis Team up on $1B Deal for Eye Drug 05/19/14 New York
Kala Pharma Grabs $22.5M More For Eye Drugs 04/23/14 Boston
East Coast Life Sciences Roundup: Foundation, Ophthotech, Sato, & More 09/27/13 Boston
Foundation Medicine, Ophthotech Both Find Open Wallets on Wall Street 09/25/13 Boston
Ophthotech Prices IPO at $22 Per Share, Reels in $167M 09/24/13 New York
Aerie Pharma Eyes $58M IPO For Glaucoma Drug Push 09/18/13 New York
East Coast Life Sciences Roundup: Genocea, Biogen, OvaScience, & More 09/13/13 Boston
East Coast Life Sciences Roundup: Epizyme, Rodin, Ophthotech, & More 08/16/13 Boston
Ophthotech Eyes $85M IPO With Late-Stage Clinical Trial in Sight 08/15/13 New York
NY Editor’s Picks: Xconomy Stories That Got This City Talking in Q2 07/03/13 New York
East Coast Life Sciences Roundup: Epizyme, Alkermes, Ophthotech, & More 05/31/13 Boston
Page 1 of 2 next page »